Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 706.4K | $1.0M | 2.55% | +19.4K | 2026-06-30 |
| AQR CAPITAL MANAGEMENT LLC | 662.2K | $1.0M | 2.39% | +391.9K | 2026-06-30 |
| BlackRock, Inc. | 311.6K | -- | 1.13% | -882.5K | 2026-06-30 |
| RAYMOND JAMES FINANCIAL INC | 213.0K | -- | 0.77% | +9.8K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 190.2K | -- | 0.69% | -304.8K | 2026-06-30 |
| GOLDMAN SACHS GROUP INC | 185.2K | -- | 0.67% | -46.3K | 2026-06-30 |
| MILLENNIUM MANAGEMENT LLC | 159.6K | -- | 0.58% | +66.9K | 2026-06-30 |
| JANE STREET GROUP, LLC | 134.2K | -- | 0.49% | +69.2K | 2026-06-30 |
| CITADEL ADVISORS LLC | 123.0K | -- | 0.44% | +110.5K | 2026-06-30 |
| UBS Group AG | 110.4K | -- | 0.40% | -142.9K | 2026-06-30 |
